Kasuga et al. investigated the discriminating utility of CSF α-synuclein in patients with primary α-synucleinopathies such as dementia with Lewy bodies and secondary α-synucleinopathies, including Alzheimer’s disease. The gene discussed is SNCA; the disease is synucleinopathy.